KineMed Inc. granted Merck & Co. Inc. nonexclusive rights to identify and develop up to 10 compounds for atherosclerosis using its reverse cholesterol transport (RCT) technology, in exchange for more than $5.5 million in initial and research payments and up to $70 million in milestones per compound. (BioWorld Today)

KineMed Inc. granted Merck & Co. Inc. nonexclusive rights to identify and develop up to 10 compounds for atherosclerosis using its reverse cholesterol transport (RCT) technology, in exchange for more than $5.5 million in initial and research payments and up to $70 million in milestones per compound. (BioWorld Today)

Sucampo Pharmaceuticals Inc. priced its initial public offering of 3.8 million shares at $11.50 each for gross proceeds of $43.1 million, half of what the company had hoped for when it first filed to go public more than a year ago. (BioWorld Today)

Sucampo Pharmaceuticals Inc. priced its initial public offering of 3.8 million shares at $11.50 each for gross proceeds of $43.1 million, half of what the company had hoped for when it first filed to go public more than a year ago. (BioWorld Today)